CROSSJECT SA EO -,10Share · FR0011716265 · A1XEH4 (XPAR) — real-time quotes, company data, dividends, fundamentals, and AI-powered portfolio analysis on MoneyPeak
Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of CROSSJECT SA EO -,10
No Price
Closing Price XPAR 30.04.2026:
1,90 EUR
30.04.2026 15:35
Current Prices from CROSSJECT SA EO -,10
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
Paris
ALCJ.PA
EUR
30.04.2026 15:35
1,90 EUR
-
Düsseldorf
CROSSJ65.DUSB
EUR
30.04.2026 06:13
1,87 EUR
-
Quotrix
CROSSJ65.DUSD
EUR
30.04.2026 05:27
1,91 EUR
-
Share Float & Liquidity
Free Float64,87 %
Shares Float34,36 M
Shares Outstanding52,96 M
Company Profile for CROSSJECT SA EO -,10 Share
Crossject Société Anonyme develops needle-free injection systems. The company develops ZENEO, a needle-free, prefilled, and single-use auto-injector. Its clinical stage drugs comprise Sumatriptan, which is used for of treatment migraines and cluster headaches; Adrenaline for treating anaphylactic shock; Hydrocortisone that is used for treatment of acute adrenal crisis; Midazolam for treating epileptic seizure; Naloxone used for treatment of overdose; Apomorphine, for treating temporary paralysis in parkinson's disease; Methotrexate used for treatment of rheumatoid arthritis; and Terbutaline, for treating severe asthma crisis. The company was founded in 1997 and is based in Dijon, France.
